Inspiration Healthcare Group PLC (LON:IHC) told investors it extended a distribution agreement and agreed a separate research collaboration relating to sick and premature babies.
According to the first announcement, the medical technology company signed a new three-year agreement to distribute infusion devices from Micrel SA in the UK and Ireland.
The products are used in a wide range of infusion therapies, including parenteral feeding, post-operative pain management, regional analgesia, chemotherapy.
Inspiration said recently it has been shifting its focus towards developing a greater share of the UK infusion therapy market and it recently won an order for 100 Micrel syringe drivers for use in chemotherapy therapy from a major NHS Trust.
“We are delighted to have extended our successful relationship with Micrel with whom we have worked for many years and are excited in the opportunities we have for continuing to grow this important part of our business as we focus on new therapy areas for their technology,” said Neil Campbell, chief executive of Inspiration.
The company also said it has signed a memorandum of understanding with the Irish Centre for Maternal and Child Health Research (INFANT) at the University College Cork (UCC) in Ireland, a research centre focused on pregnancy, birth and early childhood.
This agreement allows for Inspiration and INFANT to work together on research and innovation projects relating to sick and premature babies, helping with regulatory work and clinical user feedback.
Campbell said the company believes it can add significant value by sharing our experience and technological know-how to improve outcomes for mothers and babies.